z-logo
open-access-imgOpen Access
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Author(s) -
Joshua D. Cohen,
Lu Li,
Yuxuan Wang,
Christopher Thoburn,
Bahman Afsari,
Ludmila Danilova,
Christopher Douville,
Ammar A. Javed,
Fay Wong,
Austin K. Mattox,
Ralph H. Hruban,
Christopher L. Wolfgang,
Michael Goggins,
Marco Dal Molin,
TianLi Wang,
Richard B.S. Roden,
Alison P. Klein,
Janine Ptak,
Lisa Dobbyn,
Joy Schaefer,
Natalie Silliman,
Maria Popoli,
Joshua T Vogelstein,
J. Dale Browne,
Robert E. Schoen,
Randall E. Brand,
Jeanne Tie,
Peter Gibbs,
HuiLi Wong,
Aaron S. Mansfield,
Jin Jen,
Samir Hanash,
Massimo Falconi,
Peter J. Allen,
Shibin Zhou,
Chetan Bettegowda,
Luis A. Díaz,
Cristian Tomasetti,
Kenneth W. Kinzler,
Bert Vogelstein,
Anne Marie Len,
Nickolas Papadopoulos
Publication year - 2018
Publication title -
science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.aar3247
Subject(s) - esophagus , pancreas , medicine , cancer , stomach , ovary , blood test , gastroenterology , pancreatic cancer , stomach cancer , oncology , pathology
Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1005 patients with nonmetastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities ranged from 69 to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity of CancerSEEK was greater than 99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK localized the cancer to a small number of anatomic sites in a median of 83% of the patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom